He said the company was ‘locked and loaded’ to start manufacturing the complex gene therapy product, but was a little bit more circumspect about whether Luxturna could make money.
In December 2017, the US Food & Drug Administration (FDA) approved Luxturna from Spark Therapeutics — the first gene therapy to win market approval in the US. Several other gene therapy programs ...
The first NHS patients have started treatment with Novartis’ Luxturna, a gene therapy for a sight-robbing inherited disease, after the drugmaker agreed a discount on its £613,000 list price ...
The Dean McGee Eye Institute collaborated with OU Health to offer Gene Therapy for an eye disorder that can cause severe vision loss. The treatment is called Luxturna. It’s the first FDA ...
Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...
This approach yields a reasonable output of fully-assembled, gene therapy-ready rAAV particles ... including Spark Therapeutics’ Luxturna and a pair of other therapies now in phase 3 testing ...
Medpage Today on MSN3mon
Evidence of Durable Vision Improvement With Gene Therapy for Retinitis PigmentosaThe FDA approved the first gene therapy for RP (voretigene neparvovec, Luxturna) in 2017, but the treatment is limited to ...
Spark in late 2017 became of the first company to receive Food and Drug Administration approval for a gene therapy to treat an inherited disease. The product, called Luxturna, is used to treat a ...
He previously co-founded Spark Therapeutics and served as Chairman of the Board of Directors, where he played a key role in bringing the first and only FDA-approved retinal gene therapy, LUXTURNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback